

Non-internalizing monoclonal antibodies are suitable candidates for ^{125}I radioimmunotherapy of small-volume peritoneal carcinomatosis

Lore Santoro¹, Samir Boutaleb¹, Véronique Garambois¹, Caroline Bascoul-Mollevi², Vincent Boudousq^{1,3}, Pierre-Olivier Kotzki^{1,3}, Monique Pèlerin^{1,2}, Isabelle Navarro-Teulon¹, André Pèlerin¹ and Jean-Pierre Pouget^{1,4}

¹ IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France; INSERM, U896, Montpellier, F-34298, France; Université Montpellier1, Montpellier, F-34298, France; CRLC Val d'Aurelle Paul Lamarque, Montpellier, F-34298, France; ² CRLC Val d'Aurelle-Paul Lamarque, F-34298 Montpellier, France; ³ Service de Médecine Nucléaire, CHU de Nîmes, Nîmes F-30029, France; ⁴ Direction de la Radioprotection de l'Homme, Institut de Radioprotection et de Sécurité Nucléaire, Fontenay-aux-Roses, F-92262 France;

Running title: Radioimmunotherapy with ^{125}I -mAbs

To whom correspondence may be addressed: Jean-Pierre Pouget, Institut de Recherche en Cancérologie de Montpellier, CRLC Val d'Aurelle, 34298 Montpellier Cedex 5, France.

E-mail: jean-pierre.pouget@valdorel.fnclcc.fr

Abstract

We have previously shown that, *in vitro*, monoclonal antibodies (mAbs) labeled with the Auger electron emitter ^{125}I are more cytotoxic if they remain at the cell surface and do not internalize in the cytoplasm. Here, we assessed *in vivo* the biological efficiency of internalizing and non internalizing ^{125}I -labeled mAbs for the treatment of small solid tumors.

Methods: Swiss nude mice bearing intraperitoneal tumor cell xenografts were injected with 37 MBq (370 MBq/mg) of internalizing (anti-HER1) ^{125}I -m225 or non-internalizing (anti-CEA) ^{125}I -35A7 mAbs at day 4 and 7 following tumor cell graft. Non specific toxicity was assessed using the irrelevant ^{125}I -PX mAb and untreated controls were injected with NaCl. Tumor growth was followed by bioluminescence imaging. Mice were sacrificed when the bioluminescence signal reached a value of 4.5×10^7 photons/s. Biodistribution analysis was performed to determine the activity contained in healthy organs and tumor nodules and total cumulative decays were calculated. These values were used to calculate the irradiation dose by the MIRD formalism. **Results:** Median survival (MS) was 19 days in the NaCl-treated group. Similar values were obtained in mice treated with unlabeled PX (MS = 24 days) and 35A7 (MS = 24 days), or with ^{125}I -PX mAbs (MS = 17 days). Conversely, mice treated with unlabeled or labeled internalizing m225 mAb showed a significant increase in survival (MS = 76 days and 77 days, respectively) as well as mice injected with ^{125}I -35A7 mAb (MS = 59 days). Irradiation doses were comparable in all healthy organs independently from the mAb used, whereas, in tumors, the irradiation dose was 7.4 fold higher with ^{125}I -labeled non-internalizing than with internalizing mAbs. This discrepancy might be due to iodotyrosine moiety release occurring during the catabolism of internalizing mAbs associated to high turnover rate. **Conclusion:** This study indicates that ^{125}I -labeled non-internalizing mAbs could be suitable for radioimmunotherapy of small solid tumors, and that the use of internalizing

mAbs should not be considered as a requirement for the success of treatments with ^{125}I Auger electrons.

Keywords: radioimmunotherapy, Auger electrons, solid tumors

INTRODUCTION

Development of clinically effective radiolabeled monoclonal antibodies (mAbs) has been limited to the treatment of lymphomas. Indeed, only Zevalin and Bexxar, two anti-CD20 mAbs conjugated to ^{90}Y and ^{131}I , respectively, have been approved by the Food and Drug Administration for the therapy of lymphomas (*1*). Conversely, the few candidates for the therapy of solid tumors that have progressed to phase III clinical trials have not given clear-cut results (*2, 3, 4*).

This can be explained by inhomogeneous targeting related to poor vascularization and high interstitial pressure due to insufficient lymphatic drainage (*5-9*). Uptake of radioactivity in solid tumors is generally between 0.001% and 0.01% of the injected dose per gram of tumor and is inversely proportional to the tumor's size. In addition, solid tumors show low sensitivity to radiations. Therefore, myelotoxicity is usually attained before the dose required for tumor eradication is reached inside the cancer mass. Consequently, it is now admitted that, in case of solid tumors, radioimmunotherapy (RIT) should be considered only for the treatment of small tumors (*10, 11*), microscopic residual disease, or metastasis (*12*).

The other issue concerns the choice of emitter used to label the mAbs. The two strong energy beta emitters (i.e., ^{90}Y and ^{131}I) produce electrons having ranges between 2 and 10 mm, respectively. The long range of energetic beta particle of ^{90}Y and γ rays associated with ^{131}I are responsible for non-specific irradiation that may cause undesirable effects like myelosuppression. However, in mice, several studies showed that ^{131}I -mAbs could efficiently treat micro-metastases (size below 1mm), but not tumors of 2—3 mm in size (*13, 14*). Other emitters, like high linear energy transfer (LET) particles, may be more attractive candidate for the therapy of solid tumors. They include alpha- and Auger electron-emitting radionuclides. Alpha emitters, which are suitable for RIT, include mostly ^{212}Bi or $^{225}\text{Ac}/^{213}\text{Bi}$ and ^{211}At . Alpha particles have a short path length ($<100\text{ }\mu\text{m}$) that minimizes damage to normal tissues.

They also possess a very high LET with energy deposit of about 100 keV/ μm compared to 0.2 keV/ μm of the beta emitters [for review (15)]. However, their use in RIT requires the development of cost-effective radionuclide production and protein labeling chemistry.

Another drawback of alpha emitters is the production of radioactive daughter isotopes that can be hardly withheld in a chelator and tend to escape from targeted cells and accumulate in bone (16).

By contrast, Auger electron emitters are available for clinical use. Although Auger electron's energy ranges from eV to about 20—25 keV, those with high LET characteristics (i.e., between 4 and 26 keV/ μm) (17) have an energy comprised between few tens of eV and 1 keV and their path length in biological tissues ranges from about 2 nm to 500 nm. Therefore, in this work, we used the term “low-energy Auger electrons” to indicate this category of Auger electrons with high LET features. Several studies underscored the advantages of such emitters in comparison to conventional ^{131}I and ^{90}Y in RIT of solid tumors due to their much less toxic side effects (18-21). However, because of their short path length, their final localization within the cell has to be taken into account. Many studies using ^{125}I -iododeoxyuridine highlighted the requirement for the emitter to be located within the DNA molecule to observe a cellular toxicity similar to that of alpha particles (22). However, in RIT, the final localization of radiolabeled mAbs is either the cytoplasm or the cell surface depending on whether internalizing or non-internalizing mAbs are used. We previously showed that, *in vitro*, non-internalizing ^{125}I -mAbs were more harmful than internalizing ones. Although the strongest toxicity of ^{125}I is observed when the isotope is incorporated within the DNA molecule (23-25), these results suggest that the cell membrane also is a sensitive target (26). Here, we investigated the efficacy of non-internalizing and internalizing ^{125}I -mAbs in the treatment of mice with tumor cell xenografts. For this purpose, nude mice bearing intraperitoneal A-431-derived tumors were injected twice with 37 MBq of internalizing or

non-internalizing ^{125}I -mAbs. Tumor growth was followed by bioluminescence imaging and endpoint was a bioluminescence signal of 4.5×10^7 photons/s. Our results demonstrate that ^{125}I -mAbs are an efficient tool for the treatment of small solid tumors and that the use of internalizing ^{125}I -mAb is not a pre-requisite for RIT.

MATERIALS AND METHODS

Cell line and monoclonal antibodies

The vulvar squamous carcinoma cell line A-431 expressing the Epidermal Growth Factor Receptor (EGFR or HER1) was transfected with vectors encoding for the *CarcinoEmbryonic Antigen* (CEA) gene as described in (27) and for *luciferase* as described in (28). Cells were grown as described in (26) and medium was supplemented with 1% geneticin.

The mouse hybridoma cell line producing the m225 mAb, which binds to EGFR, was obtained from ATCC. The non-internalizing murine IgG1k 35A7 mAb, specific for the CEA Gold 2 epitope (29), was used to target CEA in transfected A-431 cells. The irrelevant PX antibody was used for control experiments. PX is an IgG1 mAb that has been purified from the mouse myeloma MOPC 21 (30). The m225, 35A7 and PX mAbs were obtained from mouse hybridoma ascites fluids by ammonium sulfate precipitation followed by ion exchange chromatography on DE52 cellulose (Whatman, Balston, United Kingdom).

Radiolabeling for therapy and biodistribution analysis

Iodine 125 (^{125}I) and Iodine 131 (^{131}I) were from Perkin Elmer (Boston, MA, USA) and mAbs were radiolabeled as described in (26). Specific activity was generally around 370 MBq/mg. For RIT, two injections of 37 MBq (equivalent to 100 μg mAb) were used. For biodistribution experiments a solution containing 185 KBq of ^{125}I -mAbs together with 320 KBq of ^{131}I -mAbs, respectively, was completed with unlabeled mAbs to a final amount of 100 μg mAbs. Immunoreactivity of ^{125}I -mAbs against CEA or EGFR was assessed *in vitro* by direct binding assays. The binding percentage was determined by measuring the antigen-bound radioactivity after 2 washes with PBS and ranged from 70 to 90%.

Animals

Swiss nude mice (6-8 week/old females) were obtained from Charles River (Lyon, France) and were acclimated for 1 week before experimental use. They were housed at 22°C and 55%

humidity with a light/dark cycle of 12h. Food and water were available *ad libitum*. Body weight was determined weekly and clinical examinations were carried out throughout the study. Experiments were performed in compliance with the French guidelines for experimental animal studies (Agreement no. B34-172-27).

Radioimmunotherapy experiments and tumor imaging

For RIT experiments, Swiss nude mice were intraperitoneally grafted with 0.7×10^6 A-431 cells suspended in 0.3 ml DMEM medium. Tumor growth was assessed 3 days after cell xenograft by bioluminescence imaging and animals were segregated in homogeneous groups according to the type of treatment (i.e., NaCl, ^{125}I -m225, ^{125}I -35A7 and ^{125}I -PX or unlabeled m225, 35A7 and PX mAbs).

Then, 37 MBq ^{125}I -mAbs (specific activity = 370 MBq/mg), NaCl or unlabelled mAbs (100 μg) were intravenously injected at day 4 and 7 after the graft. Tumor growth was followed weekly by bioluminescence imaging. Mice were sacrificed when the bioluminescence signal reached a value of 4.5×10^7 photons/s. In summary, 31 mice were included in the NaCl group, 13 in the PX, 14 in the 35A7, 7 in the m225, 19 in the ^{125}I -PX, 12 in the ^{125}I -35A7 and 6 in the ^{125}I -m225 group.

A third intravenous injection of ^{125}I -m225 or ^{125}I -35A7 mAbs was carried out in two additional groups of mice ($n=7$ for each ^{125}I -mAb) at day 10 and animals were followed until the bioluminescence signal reached a value of 4.5×10^7 photons/s or until death.

Bioluminescence imaging

In vivo bioluminescence imaging was performed following intraperitoneal injection of luciferin (0.1mg luciferin/g) and as described in (28).

Biodistribution experiments

On day 1, 48 Swiss nude mice were intraperitoneally grafted with 0.7×10^6 A-431 cells suspended in 0.3 ml DMEM medium. Mice were then separated into two groups. Group one

received one single intravenous injection of labeled mAbs at day 4, while group two received two intravenous injections (day 4 and 7). Injected solutions (250 μ L) were made up of 100 μ g of 35A7 or m225 mAbs containing 185 KBq of 125 I-mAb (specific activity = 370 MBq/mg), and of 100 μ g of irrelevant PX mAb containing 320 KBq of 131 I-PX (specific activity = 370 MBq/mg). Mice of group one were sacrificed at 1, 24, 48, 72, 96 and 168h after the injection and mice from group two at the same time points but after the second injection. At each time point, animals were anaesthetized, image acquisition was performed and then they were euthanized, bled and dissected. Blood, tumor nodules and organs were weighed and the uptake of radioactivity (i.e., $\text{UOR}_{\text{Biodis}}$) was measured with a γ -well counter. Dual isotope counting, 125 I versus 131 I, was done. The percentage of injected activity per gram of tissue (%IA/g), corrected for the radioactive decay, was calculated. For time points later than 72h (i.e., after the second injection), the injected activity of group two was defined as the sum of the residual radioactivity due to injection 1 and of the radioactivity due to injection 2. We assumed that the radioactivity detected in the different organs of mice from group 1 after this time point was not specifically bound to receptors any longer and could be mobilized again in the blood circulation. Four mice were used for each time point.

In addition, a control group of mice injected only with NaCl was sacrificed at the same time points as the animals used for the biodistribution analysis to follow the natural growth of the tumors.

Tumor weight assessment

In RIT experiments, direct measurement of tumor size could not be performed because it requires mice sacrifice and also because of the high activities. Therefore, we used the intensity of the bioluminescence signal collected weekly after tumor graft to determine tumor size. To do this we used biodistribution data to calibrate the bioluminescence signal (photons/s) as a function of tumor size. The values of the bioluminescence signal of tumor

nodules were collected at different time points during the biodistribution analysis and plotted versus their weight directly determined as follows. Initially, tumor nodules were weighed. However, these values appeared to be less accurate than estimation from size measurement because of blood or water content, or contamination by other tissues. Therefore, their length, width and depth were measured at each time point of the biodistribution study and used for volume determination. A density of 1.05g/cm^3 was then used for calculating the weight of each nodule.

Uptake of radioactivity per organ and tumor

The uptake of radioactivity per tissue (expressed in Becquerel) in RIT experiments (UOR_{RIT}) was extrapolated from the uptake per tissue ($\text{UOR}_{\text{Biodis}}$) measured during biodistribution experiments. Since activities used in RIT experiments were 200 times higher than those used in biodistribution analysis for the same amount of injected mAbs ($100\text{ }\mu\text{g}$), all the $\text{UOR}_{\text{Biodis}}$ values were multiplied by 200 to mimic the therapeutic conditions. We considered that the weight of healthy tissues did not change all along the study period and did not differ between RIT and biodistribution experimental conditions. Therefore, the 200-fold factor's rule was enough to determine the UOR_{RIT} from $\text{UOR}_{\text{Biodis}}$. However, since tumors were smaller in animals subjected to RIT than in controls, their UOR_{RIT} was calculated by taking also into consideration this weight variation. Hence, the real tumor weight was assessed as follows: $\text{UOR}_{\text{Biodis}}$ per gram of tumor was calculated by dividing $\text{UOR}_{\text{Biodis}}$ by the measured tumor weight. This value was then multiplied by the calculated weight of the tumor in RIT conditions (as described in "Tumor weight assessment"). This approach was supported by the finding that in biodistribution studies uptake of radioactivity increased in a linear way with the tumor size. Thus, we could extrapolate the UOR from large to small tumors and calculate their UOR_{RIT} . The end point of the analysis was calculated by hypothesizing that the

remaining activity at 240h would exponentially decrease to reach a value lower than 1% IA/g at 700h.

Dosimetry

The total cumulative decays per tissue were calculated by measuring the area under the UOR_{RIT} curves. Following the MIRD formalism, resulting values were multiplied by the S factor. This parameter was calculated by assuming that all the energy delivered at each decay was locally absorbed and we checked that the contribution of X and γ -rays could be neglected (31). A global energy of 19.483 keV/decay was then considered for calculating the irradiation doses.

Statistical analysis

A linear mixed regression model (LMRM), containing both fixed and random effects (32, 33), was used to determine the relationship between tumor growth (assessed by bioluminescence imaging) and number of days post-graft. The fixed part of the model included variables corresponding to the number of post-graft days and the different mAbs. Interaction terms were built into the model; random intercepts and random slopes were included to take into account time. The coefficients of the model were estimated by maximum likelihood and considered significant at the 0.05 level.

Survival rates were estimated from the date of the xenograft until the date of the event of interest (i.e., a bioluminescence value of 4.5×10^7 photons/s) using the Kaplan-Meier method. Median survival was presented and survival curves compared using the Log-rank test. Statistical analysis was performed using the STATA 10.0 software.

RESULTS

Tumor growth assessment

The presence of tumor nodules in control mice was observed as early as 3—4 days after the graft of A-431 cells (Figure 1A). Total number of tumor nodules per mouse and their size increased with time. For example, the mean number of nodules in control mice was 2.7 ± 0.9 at day 4, 4.8 ± 0.8 at day 7 and 6.6 ± 3 at day 20 after graft. Mean tumor weight was $1.4 \pm 0.9 \times 10^{-2}$ g at day 4, $4.2 \pm 0.9 \times 10^{-2}$ g at day 7 and $16 \pm 0.7 \times 10^{-2}$ g at day 20. Similar tumor growth rates were observed in mice treated with unlabeled 35A7 or PX mAbs, whereas tumor growth was much slower in the group treated with unlabeled m225. Presence of ascite was never observed throughout the study and the number of collected nodules always corresponded to the number of bioluminescence spots.

To indirectly measure tumor size in mice subjected to RIT, we calibrated the bioluminescence signal (photons/s) as a function of tumor size. We used a linear relationship to plot the signal intensity of control tumor nodules versus their weight. This procedure was satisfying only for tumors weighing less or about 1×10^{-1} g (Figure 1B). For bigger tumor nodules, the dose-response relationship was saturated and therefore tumor size was underestimated. Indeed, according to the calibration curve, the value of 4.5×10^7 photons/s should correspond to a mean tumor weight of about 2×10^{-1} g, whereas, upon dissection, the real tumor weight was $2—3 \times 10^{-1}$ g.

Tumor growth in RIT experiments

Tumor growth followed by bioluminescence imaging (Suppl. Fig. 2 A, B, C) rose similarly among mice treated with NaCl or unlabeled PX and 35A7 mAbs (Figure 2A, 2C). While no changes in tumor growth were observed with ^{125}I -PX mAbs (Figure 2C), treatment with ^{125}I -35A7 mAbs slowed down tumor growth and endpoint values of $2—3 \times 10^{-1}$ g were only

reached at day 99 after xenograft (Figure 2A). The internalizing m225 mAbs had a strong inhibitory effect on tumor growth both in the unlabeled and labeled form (Figure 2B). Indeed, mean tumor weight in mice treated with m225 mAbs remained below 2×10^{-1} g for the entire duration of the study. This could be explained by the slower and heterogeneous growth rate of tumors in m225-treated mice compared to others groups. Therefore, sacrifice of m225-treated mice was less frequent than in the other groups and the highest registered signal did not affect the global mean bioluminescence value of this group.

Survival of mice exposed to therapeutic activities of ^{125}I -labeled or unlabeled mAbs

Mice were sacrificed when the bioluminescence signal reached 4.5×10^7 photons/s. The median survival (MS) was about 19 and 24 days in mice treated with NaCl or unlabeled 35A7, respectively. Conversely, survival was significantly higher in the group treated with ^{125}I -35A7 mAbs (MS=59 days; $p=0.0132$) (Figure 3A). Both unlabeled m225 (MS=76 days; $p = 0.0014$) and ^{125}I -m225 mAbs (MS= 77 days; $p = 0.9289$) improved survival in comparison to NaCl (Figure 3B).

No statistical difference was observed in the NaCl, the 35A7, the PX or ^{125}I -PX groups ($p=0.3189$ for NaCl vs 35A7, $p = 0.9046$ for NaCl vs PX; $p = 0.5109$ for NaCl vs ^{125}I -PX; $p = 0.5095$ for PX vs ^{125}I -PX) with MS = 19, 24 and 17 days, respectively, underscoring the low non-specific toxicity of ^{125}I -mAb (Figure 3C).

To cope with the lower toxicity of Auger emitters towards the target tumors in comparison to beta emitters and to assess the side effects of repeated injections, a third injection of 37 MBq of ^{125}I -mAbs (m225 or 35A7) was carried out at day 10 following xenografts in two additional groups of mice. In this case, mice treated with ^{125}I -35A7 mAbs died before the bioluminescence signal reached 4.5×10^7 photons/s suggesting that the maximum tolerated

dose was attained and MS dropped to 14 days. Conversely, a non significant increase in MS was observed in the ^{125}I -m225 group (MS about 94 days) (data not shown).

Biodistribution analysis

After injection of non-internalizing ^{125}I -35A7 mAbs (Figure 4A), tumor uptake increased progressively from 10.5%, 1h after injection, to 48.1% after 120h. An intermediary value of 27.8% was observed at 48h. These results indicate that the maximal uptake of radioactivity per tumor was reached 2 days after the second injection.

Maximal uptake in blood was $28.1 \pm 2.4\%$ and $21.2 \pm 1.1\%$ immediately after injection 1 and 2, respectively.

By contrast, tumor uptake of internalizing ^{125}I -m225 mAbs was much lower (Figure 4B) with a maximal uptake of $17.8 \pm 6.8\%$ observed 24h after injection 1 and no increase after injection 2. Uptake in blood was maximal immediately after injection 1 and 2 with values of 30.9 ± 3.9 and $23.5 \pm 1.2\%$ like with non-internalizing mAbs.

Non specific tumor uptake of the ^{131}I -PX mAbs was comprised between 2.8 ± 0.5 and $11.5 \pm 4.6\%$ (with ^{125}I -35A7) and between 5.9 ± 3.2 and $9.7 \pm 1.8\%$ (with ^{125}I -m225) (data not shown).

For all the other organs, no significant differences were observed between the two targeting models and values were lower than those measured in tumors and blood.

Uptake of radioactivity per organ and tumor

The uptake of radioactivity per tissue (expressed in Becquerel) in RIT experiments (UOR_{RIT}) was extrapolated from the uptake per tissue ($\text{UOR}_{\text{Biodis}}$) measured during the biodistribution experiments and these values were plotted versus time (Figures 5A and B). Both targeting models presented similar UOR_{RIT} values in all tissues analyzed with the exception of tumors. Carcass, liver and blood contained the highest peak activity (10 MBq—30 MBq) because of

their larger volume (Suppl. Fig. 5A and 5B), whereas the other organs showed lower values, generally below 1.7 MBq. Maximal peak uptake by tumors reached values of 1.8 MBq with non-internalizing and of 0.05MBq with internalizing ^{125}I -mAbs. For all the tissues, two peak values corresponding to the two injections were observed.

Dosimetry

To obtain accurate information about the total energy absorbed by tumors and healthy organs we calculated their irradiation doses. The highest irradiation doses were delivered to tumors, blood, liver, skin and lungs and the lowest to small and large intestine and stomach (Figure 6). Similar irradiation doses were delivered by the two targeting models in healthy organs and tissues. Therapy with the internalizing ^{125}I -m225 mAb produced slightly higher irradiation doses in stomach (+14.4%), liver (+16.3%), kidneys (+3.5%), muscle (+31.8%), small intestine (+1.1%), large intestine (+3.9%), bone (+5.1%) and skin (+9.9%). Conversely, lower irradiation doses were calculated for lungs (-7.4%) and blood (-7.0%). For heart and carcass less than 1% discrepancy in irradiation doses was determined between both targeting models. However, a huge difference was observed in tumors since internalizing mAbs delivered only 15.1 Gy in comparison to the 111.6 Gy of non-internalizing mAbs.

DISCUSSION

In this study, we investigated the efficiency of ^{125}I -labeled internalizing and non-internalizing mAbs in eradicating small solid intraperitoneal tumors. We show that labeling of the non-internalizing 35A7 mAb was accompanied by a statistically significant increase in the median survival (MS) from 24 days (controls) to 59 days. Unlabeled m225 mAb showed by itself a very strong efficiency with a MS of 76 days that was not improved by labeling with ^{125}I . The standard treatment of patients with peritoneal carcinomatosis is based on cytoreductive surgery followed by heated intraperitoneal chemotherapy (HIPEC) (34); however, several

studies have started to compare the efficiency of RIT versus HIPEC. For instance, Aarts *et al.* targeted, in rats, carcinomatosis of about 1 mm after cytoreductive surgery with RIT or HIPEC. They obtained a MS of 97 days (versus 57 days in untreated controls) after one intraperitoneal injection of 74 MBq of ^{177}Lu - MG1 mAbs and of 76 days with HIPEC (35). Moreover, they showed that RIT was less detrimental for healthy tissues (36). Our study indicates that significant increase in MS could be achieved also with ^{125}I -mAbs and suggests that ^{125}I -mAbs could be as efficient as ^{177}Lu -mAbs in the case of small tumors.

More experiments need, however, to be performed because direct comparison between studies cannot be accurate due to the different experimental models used and, particularly, the possibility of variable radiation sensitivity of the targeted tumor cells.

Compared to conventional more energetic beta emitters, the interest of Auger electrons emitters relies on their very low myelotoxicity that allows repeated injections (18, 19). This is important as it has been speculated that the failure of phase III trial with ^{90}Y -HMFG1 in ovarian cancers was linked to the low irradiation dose delivered by a single administration [for review (37)]. Therefore, by using low-energy Auger electrons the injected activities could be increased in order to cope with their lower tumor toxicity and a therapeutic gain of about 2 in comparison to beta emitters has been already demonstrated (38). Here, we show that, in the mouse, two injections of 37 MBq of ^{125}I -mAbs are well tolerated and greatly increase MS. However, mice which received a third injection of ^{125}I -35A7 mAbs died before the bioluminescence signal reached 4.5×10^7 photons/s. These results suggest that the maximum tolerated dose was reached and that the maximal therapeutic gain, under our experimental conditions, is obtained with two injections of ^{125}I -mAbs time over 3 days. Studies are under way to determine the toxic effects of this regimen on bone marrow, although overt signs of myelotoxicity were not observed.

Conjugation to ^{125}I was accompanied by a significant increase in survival (i.e., 40 days) in the case of the non-internalizing mAb 35A7, whereas labeling did not further increase the positive effect of the internalizing mAbs m225. Moreover, the mean irradiation dose for tumors was 111.6 Gy with ^{125}I -35A7 and 15.1 Gy with ^{125}I -m225. These findings indicate that labeling m225 with ^{125}I does not improve its therapeutic efficiency, mainly because the delivered irradiation dose was too low. This was not due to lack of EGFR expression in A-431 cells because flow cytometry analysis revealed that CEA and HER1 antigens were expressed at similar level (Figure 1A). Since 35A7 and m225 immunoreactivity and immunoaffinity are comparable *in vitro*, we think that catabolism of internalizing mAbs must have been the cause of the low number of total cumulative decays in tumors treated with ^{125}I -m225, an effect linked to its short retention time within the tumor. Indeed, the %IA/g of tumors reached 48.1% with ^{125}I -35A7, but only 17.8% with ^{125}I -m225. Internalizing ^{125}I -mAbs are catabolized within the cells and one of the catabolism products is a diffusible iodotyrosine moiety. Methodologies aimed at producing residualizing peptides, which can be conjugated to mAbs before the iodination process, have been developed. In this case, catabolism produces iodinated residual peptides that are trapped within the lysosomes to increase tumor retention time (39-42). However, with residualizing peptides tumor irradiation could be increased by a factor of 3-4, while in our study a 7.4 fold increase (i.e., from 15.1 Gy to 111.6 Gy) was observed with non-internalizing mAbs in comparison to internalizing mAbs. Moreover, the high turnover rate of cell surface antigens represent a limiting factor for mAb penetration within solid tumors (43).

Nevertheless, the limits of dosimetry in the case of Auger electrons must be kept in mind. Indeed, since most of the energy is delivered within a sphere of several nm around the decay site, the calculation of the mean irradiation dose for an organ or even for a cell could lead to approximations that do not take into account the real dose distribution. If this type of

approximation is acceptable in the case of low LET radiations, like gamma rays, the correlation between mean irradiation dose and biological effects must be used carefully in the case of high LET particles, particularly in the case of low-energy Auger electrons. Indeed, due to the strong heterogeneity of the energy deposits, some areas of a tumor nodule could be not irradiated and cells therein could grow in spite of a high mean tumor dose. In our study, mean calculated irradiation doses might appear rather high. This can be explained by a strong initial uptake of ^{125}I -35A7 mAb by tumors (48.1%) that led us to consider a long interval (700h) before reaching the endpoint of 1% IA/g of tumor. Then, dose rate is finally rather low and would explain the lack of overt toxicities towards safe tissues. Behr *et al.* have reported radiation absorbed doses to the blood up to 24.3 Gy in mice administered ^{125}I -CO17-1A mAbs at a maximum tolerated dose of 111 MBq (18). These radiation absorbed doses are almost identical to those estimated for ^{125}I -35A7 mAb using a similar observation period of 500 h (20.1 Gy; not shown) but exceed by about 10-fold those normally found to be dose-limiting for energetic β -emitters, indicating a different relationship between radiation absorbed dose and biological effect for Auger electron emitters.

Another point could be that inhomogeneous UOR in solid tumors could alter the linearity of the relationship between tumor mass and UOR that was used for dosimetric assessment.

Therefore calculated irradiation doses could be overestimated.

Our study is in agreement with our previous *in vitro* study showing that the cell membrane (targeted by non-internalizing mAbs) was sensitive to ^{125}I decays (26). Non-internalizing ^{125}I -mAbs might produce strong energy deposits which are localized at the cell membrane, while internalizing ^{125}I -mAbs mostly segregate within lysosomes. However, these conclusions cannot probably be extrapolated to other Auger electron emitters, like ^{111}In , ^{123}I or ^{67}Ga . Indeed, although their disintegration produces 8, 11 and 20 Auger electrons, respectively, with energy ranging from 12eV to 24 keV [for review (44)], their decays are also associated

to more or less energetic photons rays or conversion electrons that contribute mostly to the irradiation dose. For this reason, ^{125}I can be considered the Auger electrons emitter that produces the most localized energy deposits and the lowest toxic side effects. One of the main drawbacks of ^{125}I for clinical use is its rather long physical period. However, this could be minimized if ^{125}I -mAbs were administered following HIPEC, because the latter procedure allows to remove non-cell bound radiolabeled antibody from the peritoneal cavity.

Conclusion

We show that growth of solid tumors can be significantly reduced and survival of mice improved by RIT with ^{125}I -labeled non-internalizing mAbs.

Catabolism of internalizing ^{125}I - mAbs, labeled with non-residualizing labeling methods, release diffusible iodotyrosine moieties. This might explain the drastically reduced efficiency of these antibodies in our study, preventing accurate comparison between cytoplasmic and cell surface localizations. However, these results confirm our previous *in vitro* work showing that the cell membrane is sensitive to ^{125}I decays. They indicate that the use of internalizing mAbs, that drive radioactivity in cell in close proximity to the nucleus, is not a pre-requisite to the success of a therapy with ^{125}I .

ACKNOWLEDGMENTS

This work was supported by the Electricité de France-Service de Radioprotection. The authors would like to thank Imade Ait Arsa for animals care and involvement in experiments.

REFERENCES

1. Davies AJ. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. *Oncogene*. May 28 2007;26(25):3614-3628.
2. Oei AL, Verheijen RH, Seiden MV, et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. *Int J Cancer*. Jun 15 2007;120(12):2710-2714.
3. Verheijen RH, Massuger LF, Benigno BB, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. *J Clin Oncol*. Feb 1 2006;24(4):571-578.
4. Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC. Antibody-guided radiation therapy of cancer. *Cancer Metastasis Rev*. Dec 2005;24(4):539-567.
5. Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. *Nat Rev Cancer*. Apr 2008;8(4):309-316.
6. Williams LE, Bares RB, Fass J, Hauptmann S, Schumpelick V, Buell U. Uptake of radiolabeled anti-CEA antibodies in human colorectal primary tumors as a function of tumor mass. *Eur J Nucl Med*. Apr 1993;20(4):345-347.
7. Jain M, Venkatraman G, Batra SK. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. *Clin Cancer Res*. Mar 1 2007;13(5):1374-1382.
8. Jain R. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. *Cancer Res*. 1990 Fév 1990;50(3 Suppl):814s-819s.
9. Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. *J Nucl Med*. Jun 2007;48(6):995-999.
10. Sharkey RM, Pykett MJ, Siegel JA, Alger EA, Primus FJ, Goldenberg DM. Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. *Cancer Res*. Nov 1 1987;47(21):5672-5677.
11. Koppe M. Radioimmunotherapy and colorectal cancer. *Br J Surg*. Mar 2005;92(3):264-276.
12. Behr TM, Liersch T, Greiner-Bechert L, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. *Cancer*. Feb 15 2002;94(4 Suppl):1373-1381.
13. Sharkey RM, Weadock KS, Natale A, et al. Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. *J Natl Cancer Inst*. May 1 1991;83(9):627-632.

14. Vogel CA, Galmiche MC, Buchegger F. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. *Cancer Res.* Feb 1 1997;57(3):447-453.
15. Couturier O, Supiot S, Degraef-Mougin M, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. *Eur J Nucl Med Mol Imaging.* May 2005;32(5):601-614.
16. Sofou S, Kappel BJ, Jaggi JS, McDevitt MR, Scheinberg DA, Sgouros G. Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers. *Bioconjug Chem.* Nov-Dec 2007;18(6):2061-2067.
17. Kassis AI. Radiotargeting agents for cancer therapy. *Expert Opin Drug Deliv.* Nov 2005;2(6):981-991.
18. Behr TM, Sgouros G, Vougiokas V, et al. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model. *Int J Cancer.* May 29 1998;76(5):738-748.
19. Behr TM, Behe M, Lohr M, et al. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. *Eur J Nucl Med.* Jul 2000;27(7):753-765.
20. Michel RB, Brechbiel MW, Mattes MJ. A comparison of 4 radionuclides conjugated to antibodies for single-cell kill. *J Nucl Med.* Apr 2003;44(4):632-640.
21. Michel RB, Castillo ME, Andrews PM, Mattes MJ. In vitro toxicity of A-431 carcinoma cells with antibodies to epidermal growth factor receptor and epithelial glycoprotein-1 conjugated to radionuclides emitting low-energy electrons. *Clin Cancer Res.* Sep 1 2004;10(17):5957-5966.
22. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. *J Nucl Med.* Jan 2005;46 Suppl 1:4S-12S.
23. Kassis AI. Radiotargeting agents for cancer therapy. *Expert Opin drug deliv.* 2005;2(6):981-991.
24. Hofer KG. Biophysical aspects of Auger processes. *Acta Oncol.* 2000;39(6):651-657.
25. Hofer KG, Lin X, Schneiderman MH. Paradoxical effects of iodine-125 decays in parent and daughter DNA: a new target model for radiation damage. *Radiat Res.* Apr 2000;153(4):428-435.
26. Pouget JP, Santoro L, Raymond L, et al. Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. *Radiat Res.* Aug 2008;170(2):192-200.
27. Pelegrin A, Terskikh A, Hayoz D, et al. Human carcinoembryonic antigen cDNA expressed in rat carcinoma cells can function as target antigen for tumor localization of

- antibodies in nude rats and as rejection antigen in syngeneic rats. *Int J Cancer*. 1992;52(1):110-119.
28. Pillon A, Servant N, Vignon F, Balaguer P, Nicolas JC. In vivo bioluminescence imaging to evaluate estrogenic activities of endocrine disrupters. *Anal Biochem*. May 15 2005;340(2):295-302.
 29. Hammarstrom S, Shively JE, Paxton RJ, et al. Antigenic sites in carcinoembryonic antigen. *Cancer Res*. Sep 1 1989;49(17):4852-4858.
 30. Kohler G, Howe SC, Milstein C. Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. *Eur J Immunol*. Apr 1976;6(4):292-295.
 31. Boutaleb S, Pouget JP, Hindorf C, et al. Impact of mouse model on pre-clinical dosimetry in Targeted Radionuclide Therapy. *Proceedings of the IEEE*. 2009;in press.
 32. Mc Culloch C SS. Generalized, linear, and mixed models. *New York: 2001*.
 33. Laird NM, Ware JH. Random-effects models for longitudinal data. *Biometrics*. Dec 1982;38(4):963-974.
 34. Ceelen WP, Hesse U, de Hemptinne B, Pattyn P. Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer. *Br J Surg*. Aug 2000;87(8):1006-1015.
 35. Aarts F, Hendriks T, Boerman OC, Koppe MJ, Oyen WJ, Bleichrodt RP. A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. *Ann Surg Oncol*. Nov 2007;14(11):3274-3282.
 36. Aarts F, Bleichrodt RP, de Man B, Lomme R, Boerman OC, Hendriks T. The Effects of Adjuvant Experimental Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy on Intestinal and Abdominal Healing after Cytoreductive Surgery for Peritoneal Carcinomatosis in the Rat. *Ann Surg Oncol*. Aug 19 2008.
 37. Meredith RF, Buchsbaum DJ, Alvarez RD, LoBuglio AF. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. *Clin Cancer Res*. Sep 15 2007;13(18 Pt 2):5643s-5645s.
 38. Barendswaard EC, Humm JL, O'Donoghue JA, et al. Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. *J Nucl Med*. Aug 2001;42(8):1251-1256.
 39. Stein R, Govindan SV, Mattes MJ, et al. Improved iodine radiolabels for monoclonal antibody therapy. *Cancer Res*. Jan 1 2003;63(1):111-118.
 40. Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. *Nucl Med Biol*. Jan 2002;29(1):1-11.

- 41.** Sharkey RM, Karacay H, Cardillo TM, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. *Clin Cancer Res.* Oct 1 2005;11(19 Pt 2):7109s-7121s.
- 42.** Kurth M, Pelegrin A, Rose K, et al. Site-specific conjugation of a radioiodinated phenethylamine derivative to a monoclonal antibody results in increased radioactivity localization in tumor. *J Med Chem.* Apr 30 1993;36(9):1255-1261.
- 43.** Ackerman ME, Pawlowski D, Wittrup KD. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. *Mol Cancer Ther.* Jul 2008;7(7):2233-2240.
- 44.** Kassis AI. Cancer therapy with Auger electrons: are we almost there? *J Nucl Med.* Sep 2003;44(9):1479-1481.

Figure legends

Figure 1. Tumor growth and bioluminescence calibration curves. A) Swiss nude mice bearing 1—2 mm xenograft A-431 tumor nodules were followed by bioluminescence imaging. Flow cytometry analysis (inset) indicated similar levels of expression of EGFR and CEA receptors at the surface of A-431 cells. B) *In vivo* relationship between bioluminescence signal and mean tumor weight per mouse.

Figure 2. Swiss nude mice bearing intraperitoneal A-431 tumor cell xenografts were injected twice with 37 MBq of ^{125}I -mAbs (370 MBq/mg) or with unlabelled mAbs (100 μg). A) non-internalizing 35A7 mAbs, B) internalizing m225 mAbs, C) irrelevant PX mAbs. Untreated controls were injected with NaCl. Tumor growth was followed by bioluminescence imaging. The corresponding mean tumor weights were next calculated using the calibration curve reported in Figure 1B and they are shown as a function of time in A, B, C, respectively..

Figure 3. Swiss nude mice bearing intraperitoneal A-431 tumor cell xenografts were intravenously injected twice with 37 MBq of ^{125}I -mAbs (370 MBq/mg) or with unlabeled mAb (100 μg). A) Non-internalizing 35A7 mAbs, B) Internalizing m225 mAbs, C) Irrelevant PX mAb. Survival rates were estimated using the Kaplan-Meier method. Mice were sacrificed when bioluminescence signal reached 4.5×10^7 photons /second. **Censored mice are indicated on the graph by vertical bars.**

Figure 4. Biodistribution. Swiss nude mice bearing intraperitoneal A-431 tumor cell xenografts were intravenously injected twice with a solution containing specific ^{125}I -mAbs or irrelevant ^{131}I -PX as described in Materials and Methods. The percentage of injected activity per gram of tissue (%IA/g tissue) was determined in healthy organs and tumors. A)

Non internalizing ^{125}I -mAbs. B) Internalizing ^{125}I -mAbs. Four mice were analyzed at each time point.

Figure 5. Uptake of radioactivity. Uptake of radioactivity per tissue (Bq) was determined using the values obtained during the biodistribution experiments (see Figure 4) as described in Materials and Methods. A) Non internalizing ^{125}I -mAbs. B) Internalizing ^{125}I -mAbs.

Figure 6. MIRD dose calculation. From Figure 5, total cumulative decays per tissue, \tilde{A} , was calculated by measuring the area under each curve. \tilde{A} was next multiplied by 19.483 keV, corresponding to the mean energy delivered at each ^{125}I decay.